Gold Alexander M 4

4 · Mineralys Therapeutics, Inc. · Filed Nov 13, 2025

Form 4

Period: 2025-11-11

Director

Transactions

Sale
Common Stock
2025-11-13$46.50/sh−12,742$592,503→ 0 total
Exercise/Conversion
Stock Option
2025-11-11−15,000→ 17,900 total
Exercise: $10.20Exp: 2035-02-13→ Common Stock (15,000 underlying)
Exercise/Conversion
Stock Option
2025-11-12−6,933→ 10,967 total
Exercise: $10.20Exp: 2035-02-13→ Common Stock (6,933 underlying)
Exercise/Conversion
Stock Option
2025-11-13−2,742→ 8,225 total
Exercise: $10.20Exp: 2035-02-13→ Common Stock (2,742 underlying)
Exercise/Conversion
Common Stock
2025-11-11$10.20/sh+15,000$153,000→ 15,000 total
Sale
Common Stock
2025-11-11$47.08/sh−5,000$235,408→ 0 total
Sale
Common Stock
2025-11-12$47.28/sh−1,933$91,386→ 0 total
Exercise/Conversion
Common Stock
2025-11-12$10.20/sh+6,933$70,717→ 6,933 total
Sale
Common Stock
2025-11-11$42.43/sh−10,000$424,298→ 5,000 total
Sale
Common Stock
2025-11-12$46.50/sh−5,000$232,500→ 1,933 total
Exercise/Conversion
Common Stock
2025-11-13$12.69/sh+10,000$126,900→ 12,742 total
Exercise/Conversion
Stock Option
2025-11-13−10,000→ 34,000 total
Exercise: $12.69Exp: 2034-06-13→ Common Stock (10,000 underlying)
Exercise/Conversion
Common Stock
2025-11-13$10.20/sh+2,742$27,968→ 2,742 total

Footnotes (2)

[F1]The stock option vests in 12 monthly installments following the date of grant.
[F2]The stock option vests in 36 monthly installments beginning on July 13, 2024.

Documents

1 file